GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (NAS:ESPR) » Definitions » PS Ratio

Esperion Therapeutics (Esperion Therapeutics) PS Ratio

: 1.71 (As of Today)
View and export this data going back to 2013. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Esperion Therapeutics's share price is $1.945. Esperion Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.14. Hence, Esperion Therapeutics's PS Ratio for today is 1.71.

The historical rank and industry rank for Esperion Therapeutics's PS Ratio or its related term are showing as below:

ESPR' s PS Ratio Range Over the Past 10 Years
Min: 0.7   Med: 3.97   Max: 266.11
Current: 1.76

During the past 13 years, Esperion Therapeutics's highest PS Ratio was 266.11. The lowest was 0.70. And the median was 3.97.

ESPR's PS Ratio is ranked better than
58.11% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 2.16 vs ESPR: 1.76

Esperion Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.29. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.14.

Warning Sign:

Esperion Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Esperion Therapeutics was -0.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was -48.50% per year.

During the past 13 years, Esperion Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -40.80% per year. The lowest was -48.50% per year. And the median was -44.65% per year.

Back to Basics: PS Ratio


Esperion Therapeutics PS Ratio Historical Data

The historical data trend for Esperion Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.89 3.14 1.84 5.48 2.65

Esperion Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.48 1.39 1.28 0.89 2.65

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics PS Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's PS Ratio falls into.



Esperion Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Esperion Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.945/1.137
=1.71

Esperion Therapeutics's Share Price of today is $1.945.
Esperion Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Esperion Therapeutics  (NAS:ESPR) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Esperion Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (Esperion Therapeutics) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Executives
Eric Warren officer: Chief Commercial Officer 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
J Martin Carroll director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Sheldon L. Koenig officer: Chief Operating Officer C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joanne M. Foody officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Benjamin Looker officer: General Counsel C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Benjamin Halladay officer: Chief Financial Officer ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Alan Fuhrman director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben director, officer: Pres & Chief Executive Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Tracy M Woody director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
Richard Bartram officer: Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121